Literature DB >> 31997099

The Management Approach to the Adolescent IBD Patient: Health Maintenance and Medication Considerations.

Joshua M Steinberg1, Aline Charabaty2.   

Abstract

PURPOSE OF REVIEW: Inflammatory bowel disease (IBD) is often diagnosed during adolescence and can have a deep impact on the physical, hormonal, developmental, and psychosocial changes associated with this life period. The purpose of this review is to address the particular manifestations of IBD (such as growth and pubertal delay), health maintenance issues, and treatment considerations in the adolescent. RECENT
FINDINGS: The need for a multidisciplinary approach to recognize and address growth and pubertal delay, bone health, as well as the psychosocial impact of IBD on the adolescent has been increasingly recognized as an integral part of IBD care in this population. Vaccinations schedule, preventive health measures, and promoting compliance with care are particularly important during adolescence. Replacing nutrients deficits is also crucial: in particular, vitamin D has been shown to play a role in the gut immune system, and adequate vitamin D levels might promote IBD remission. Iron replacement should be done by intravenous route since oral iron is poorly absorbed in chronic inflammatory states. Finally, recent data have shed light on the increased risk of particular types of lymphoma in adolescent on thiopurines, whereas biologic therapies, in particular, anti-TNF, now are positioned as a preferred and effective steroid-sparing agents in moderate to severe IBD. Management of adolescents with IBD is not without significant challenges. An early implementation of steroid-sparing therapies, a multidisciplinary treatment approach, and a dynamic physician-patient relationship are essential to achieve remission, prevent disease-related complications but also optimize developmental, physical, and psychosocial health, and encourage compliance and transition to adult care.

Entities:  

Keywords:  Adolescent IBD; Adolescent health maintenance; Adolescent medicine; Crohn’s disease; IBD; Inflammatory bowel disease; Pediatric IBD; Ulcerative colitis

Mesh:

Year:  2020        PMID: 31997099     DOI: 10.1007/s11894-019-0739-9

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  50 in total

1.  Use of enteral nutrition for the control of intestinal inflammation in pediatric Crohn disease.

Authors:  Jeff Critch; Andrew S Day; Anthony Otley; Cynthia King-Moore; Jonathan E Teitelbaum; Harohalli Shashidhar
Journal:  J Pediatr Gastroenterol Nutr       Date:  2012-02       Impact factor: 2.839

2.  Impaired bone health in inflammatory bowel disease: a case-control study in 80 pediatric patients.

Authors:  Saila Laakso; Helena Valta; Matti Verkasalo; Sanna Toiviainen-Salo; Heli Viljakainen; Outi Mäkitie
Journal:  Calcif Tissue Int       Date:  2012-06-23       Impact factor: 4.333

3.  Cognitive-behavioral therapy for adolescents with inflammatory bowel disease and subsyndromal depression.

Authors:  Eva Szigethy; Elyse Kenney; Johanna Carpenter; Diana M Hardy; Diane Fairclough; Athos Bousvaros; David Keljo; John Weisz; William R Beardslee; Robert Noll; David Ray DeMASO
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2007-10       Impact factor: 8.829

4.  Methotrexate for the Treatment of Pediatric Crohn's Disease: A Systematic Review and Meta-analysis.

Authors:  Ruben J Colman; Rachel C Lawton; Marla C Dubinsky; David T Rubin
Journal:  Inflamm Bowel Dis       Date:  2018-09-15       Impact factor: 5.325

5.  The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.

Authors:  Daniël R Hoekman; Johannan F Brandse; Tim G de Meij; Thalia Z Hummel; Mark Löwenberg; Marc A Benninga; Geert R D'Haens; Angelika Kindermann
Journal:  Scand J Gastroenterol       Date:  2015-04-11       Impact factor: 2.423

6.  Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.

Authors:  Jeffrey Hyams; Wallace Crandall; Subra Kugathasan; Anne Griffiths; Allan Olson; Jewel Johanns; Grace Liu; Suzanne Travers; Robert Heuschkel; James Markowitz; Stanley Cohen; Harland Winter; Gigi Veereman-Wauters; George Ferry; Robert Baldassano
Journal:  Gastroenterology       Date:  2006-12-03       Impact factor: 22.682

Review 7.  Bone Health in Patients With Inflammatory Bowel Diseases.

Authors:  Victor G Chedid; Sunanda V Kane
Journal:  J Clin Densitom       Date:  2019-07-13       Impact factor: 2.617

8.  Oral tacrolimus for pediatric steroid-resistant ulcerative colitis.

Authors:  V M Navas-López; J Blasco Alonso; M J Serrano Nieto; F Girón Fernández-Crehuet; M D Argos Rodriguez; C Sierra Salinas
Journal:  J Crohns Colitis       Date:  2013-04-09       Impact factor: 9.071

Review 9.  Aminosalicylates for induction of remission or response in Crohn's disease.

Authors:  Wee-Chian Lim; Yongjun Wang; John K MacDonald; Stephen Hanauer
Journal:  Cochrane Database Syst Rev       Date:  2016-07-03

10.  Treatment of Active Crohn's Disease with Exclusive and Partial Enteral Nutrition: A Pilot Study in Adults.

Authors:  Catherine L Wall; Richard B Gearry; Andrew S Day
Journal:  Inflamm Intest Dis       Date:  2018-06-26
View more
  1 in total

Review 1.  Telemedicine and Integrated Multidisciplinary Care for Pediatric IBD Patients: A Review.

Authors:  Lauren M Potthoff
Journal:  Children (Basel)       Date:  2021-04-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.